Yahoo Web Search

  1. Ads
    related to Leukemia
  1. Edited Transcript of ADPT.OQ earnings conference call or presentation 13-Aug-19 8:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 13 12:03 PM

    To build this market leadership for clonoSEQ, we are pursuing FDA approval to expand our label to include a third indication: chronic lymphocytic leukemia or CLL in blood by year-end ...

  2. Edited Transcript of MOR.DE earnings conference call or presentation 30-Oct-19 1:00pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 12 1:57 AM

    The other ongoing trials with tafasitamab are the Phase 3 B-MIND trial, also in relapsed or refractory DLBCL; and the COSMOS trial, the Phase 2 trial focusing on patients with chronic lymphocytic ...

  3. Edited Transcript of SGNL earnings conference call or presentation 7-Nov-19 9:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 15 7:48 AM

    The data we've released to date showed durability of disease stabilization observed in patients with the aggressive subtypes of ATLL and support our belief that cobomarsen may be a meaningful ...

  4. Edited Transcript of GTXI earnings conference call or presentation 7-Nov-19 10:00pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 16 1:51 AM

    We will present additional interim data from our ongoing Phase I/II clinical trial of cirmtuzumab in combination with ibrutinib in patients with CLL or MCL at the American Society of Hematology ...

  5. Edited Transcript of VSTM earnings conference call or presentation 29-Oct-19 8:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 16 4:16 AM

    Overall, we are highly encouraged by COPIKTRA's positive upward sales trajectory, and we continue to believe in our peak annual sales estimates of $200 million to $300 million for the current ...

  6. Edited Transcript of XNCR earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 15 23:34 PM

    It's in an open-label, Phase I, dose-escalation study to assess safety, tolerability and preliminary antitumor activity in patients with relapsed/refractory acute myeloid leukemia as ...

  7. Edited Transcript of SNSS earnings conference call or presentation 12-Nov-19 9:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceNov 15 23:35 PM

    Recently, we have made great progress in the dose escalation portion of our Phase Ib/II trial of vecabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, or CLL ...

  1. Ads
    related to Leukemia